Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail tested in battle against recurrent uterine cancer

NCT ID NCT03008408

Summary

This study is testing whether adding a drug called ribociclib to a two-drug combination (everolimus and letrozole) works better to control advanced or recurrent endometrial cancer. It involves about 90 patients whose cancer has spread or returned. The goal is to see if the three-drug combination stops tumor growth longer and is safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Lyndon Baines Johnson General Hospital

    Houston, Texas, 77026-1967, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.